KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Amortizatization of Intangibles (2020 - 2025)

Historic Amortizatization of Intangibles for AbCellera Biologics (ABCL) over the last 6 years, with Q3 2025 value amounting to $2.0 million.

  • AbCellera Biologics' Amortizatization of Intangibles fell 9398.52% to $2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.3 million, marking a year-over-year decrease of 7857.76%. This contributed to the annual value of $78.3 million for FY2024, which is 57295.69% up from last year.
  • As of Q3 2025, AbCellera Biologics' Amortizatization of Intangibles stood at $2.0 million, which was down 9398.52% from $1.6 million recorded in Q2 2025.
  • Over the past 5 years, AbCellera Biologics' Amortizatization of Intangibles peaked at $33.1 million during Q3 2024, and registered a low of $1.3 million during Q1 2025.
  • Its 5-year average for Amortizatization of Intangibles is $6.5 million, with a median of $2.6 million in 2021.
  • As far as peak fluctuations go, AbCellera Biologics' Amortizatization of Intangibles soared by 234059.41% in 2021, and later crashed by 9516.15% in 2025.
  • AbCellera Biologics' Amortizatization of Intangibles (Quarter) stood at $2.6 million in 2021, then skyrocketed by 320.0% to $11.0 million in 2022, then crashed by 66.94% to $3.7 million in 2023, then surged by 186.53% to $10.5 million in 2024, then crashed by 80.98% to $2.0 million in 2025.
  • Its Amortizatization of Intangibles stands at $2.0 million for Q3 2025, versus $1.6 million for Q2 2025 and $1.3 million for Q1 2025.